Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901092 · ClinicalTrials.gov registry record · Phase 3
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
A Phase 3 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
- 1
- Study location
NCT03901092 is a Phase 3 study of Alzheimer Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 242 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03901092, a Phase 3 study of Alzheimer Disease, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
Conditions Studied
Interventions
- DRUG flortaucipir F 18
Study Locations (1)
Pennsylvania
- American College of Radiology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03901092
The ClinicalTrials.gov registry entry for NCT03901092 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower). The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which flortaucipir F 18 is the first listed.
NCT03901092 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03901092 about?
NCT03901092 is a clinical study titled "A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation". This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
What is the current status of trial NCT03901092?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2019-03-26. Estimated completion is 2019-04-26.
What conditions does trial NCT03901092 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03901092?
The interventions under investigation include: flortaucipir F 18 (DRUG).
Who is sponsoring clinical trial NCT03901092?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03901092 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Epidemiology and Biomarker Study in Alzheimer's Disease
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.